Apr. 3 at 1:52 AM
$OSTX They just removed what many saw as the biggest overhang: financing.
The company closed a
$5.25M registered direct (~
$4.7M net), with repeat high-net-worth investor participation—strong signal of continued conviction.
This isn’t standalone capital:
• ~
$4M in expected non-dilutive VAT + R&D refunds in 2026
• Combined runway now extends into 2027
OSTX is now funded through:
• FDA Type B pre-BLA meeting
• Entire BLA Process
• Key US/EU/UK regulatory steps
• Progress toward potential PRV
-OSAH Spinoff
This shifts the narrative:
→ No immediate financing risk
→ Reduced dilution uncertainty
→ Full focus on execution
With data already submitted and the Type B meeting ahead, the setup becomes regulatory—not survival.
Historically, small-cap biotechs re-rate into FDA alignment once funding is secured.
Don’t be surprised if the trading behavior starts to look drastically different with the page turning from dilution to a major inflection point in May. 📈📈📈
